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INTRODUCTION
Better secondary prevention after myocardial 
infarction (MI) could prevent over 30 000 
deaths a year in England and Wales.1 GPs 
have a crucial role and should be aware of 
recent changes in recommended antiplatelet 
therapy.
PHARMACOLOGICAL SECONDARY 
PREVENTION
There is no ‘one-size-fits-all’ secondary 
preventative drug regimen, owing to the 
ranging presentations of MI (ST-segment 
elevation [STEMI] and non-ST-segment 
elevation [NSTEMI]), the timing of reperfusion 
therapy (emergency versus urgent 
percutaneous coronary intervention [PCI] or 
coronary artery bypass surgery [CABG]), and 
the range of comorbidities (such as, heart 
failure, atrial fibrillation, or hypertension).
Currently in the UK, >80% of STEMI 
patients receive primary PCI, with <1% 
receiving urgent CABG. Among NSTEMI 
patients, more than 90% receive some form 
of anticoagulation and approximately one-
third undergo revascularisation (Box 1).2
Most patients will need dual antiplatelet 
therapy (DAPT) for 12 months, an 
angiotensin-converting enzyme inhibitor 
(ACEI), a beta-blocker, and a statin, all of 
which have been shown to reduce the risk of 
coronary death.3
Antiplatelets
Aspirin should be commenced immediately 
and continued lifelong in all patients post-MI 
unless aspirin intolerant, when clopidogrel is 
recommended.3
DAPT is indicated in all patients. DAPT 
has traditionally combined aspirin with 
clopidogrel, but newer agents (for example, 
ticagrelor) have emerged as favourable 
alternatives to clopidogrel, with fewer major 
adverse cardiovascular events.
Up to 12 months of DAPT with aspirin 
and ticagrelor is recommended in NSTEMI 
and STEMI patients following treatment with 
either PCI or CABG.
DAPT with aspirin and clopidogrel is now 
only recommended in NSTEMI and STEMI 
patients who cannot receive ticagrelor 
(previous intracranial haemorrhage or 
ongoing bleeds) or in patients who require 
oral anticoagulation.4
In patients with a high bleeding risk, the 
patient’s cardiologist may advise a shorter 
DAPT duration of 6 months.4 Conversely, 
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Box 1. UK reperfusion recommendations and antiplatelet therapya
Role Details Comment
STEMI5 •  Eligible patients must have timely reperfusion (primary PCI or 
fibrinolysis)
•  If ineligible for reperfusion therapy, conservative medical therapy 
should be offered
•  If >12 hours of symptom onset with evidence of ongoing 
ischaemia or cardiogenic shock, consider angiography ± primary  
PCI if indicated or with a view to CABG
Aspirin 75 mg 
daily for life plus: 
ticagrelor 90 mg 
twice daily for a 
year
NSTEMI6 •  All NSTEMI patients should be risk-stratified
•  Intermediate or high-risk patients should undergo coronary 
angiography (± PCI if indicated) within 96 hours of presentation 
or sooner if clinically unstable
•  Low-risk patients should be offered conservative management 
only without early coronary angiography
Aspirin 75 mg 
daily for life plus: 
ticagrelor 90 mg 
twice daily for a 
year
aFrom NICE guidelines. CABG = coronary artery bypass surgery. NSTEMI = non-ST-segment elevation. 
STEMI = ST-segment elevation. PCI = percutaneous coronary intervention.
in patients at high risk of major adverse 
cardiovascular events (patients with diabetes, 
multivessel disease, or congestive cardiac 
failure) and low risk of bleeding (young age), 
longer DAPT beyond 12 months may be 
advised.4
Patients at high risk of gastrointestinal 
bleeding should be placed on a proton pump 
inhibitor alongside antiplatelet agents.3 
Omeprazole interacts with clopidogrel, 
so lansoprazole should be used in these 
patients.
Anticoagulants
Anticoagulants are only indicated for a left 
ventricular (LV) thrombus or comorbid 
conditions (such as atrial fibrillation or 
deep vein thrombosis). Co-prescription of 
antiplatelets and anticoagulants results in 
a very high bleeding risk, and are currently 
tailored on an individual basis by a cardiologist. 
A typical regimen would be 3 months of triple 
therapy (aspirin, clopidogrel, and warfarin), 
followed by lifelong clopidogrel and warfarin. 
Angiotensin-converting enzyme inhibitors 
and angiotensin receptor blockers
An ACEI (for example, ramipril), or 
angiotensin receptor blocker (ARB) (for 
example, candesartan) if intolerant, should 
be up-titrated to a maximum tolerated 
dose while monitoring renal function. It is 
indicated lifelong in all patients with systolic 
dysfunction (LV ejection fraction <40%).3
Beta-blockers
A cardioselective beta-blocker (for example, 
bisoprolol) should be commenced in all 
patients once haemodynamically stable and 
up-titrated to a maximum tolerated dose. 
This should be continued for 12 months, or 
lifelong if evidence of systolic dysfunction.3 
Statin
A statin (for example, atorvastatin) should be 
commenced in all patients post-MI without 
delay, regardless of lipid profile. A lipid 
profile should be performed at 4–6 weeks 
post-MI. Additional lipid-lowering agents 
should be introduced in cases of refractory 
dyslipidaemia (LDL ≥1.8 mmol/L).4 
HEALTH PROMOTION
All patients should be offered:
• smoking cessation counselling if needed3 
as smoking cessation halves the risk of 
recurrent MI;7
• a structured programme of cardiac 
rehabilitation within 10 days of discharge, 
incorporating stress management and 
regular cardiorespiratory exercise (20–
30 minutes per day of physical activity 
to the point of slight breathlessness). 
Exercise is deemed safe even in those with 
LV dysfunction, provided they are stable;3
• dietary advice: a ‘Mediterranean-
style’ diet is recommended (increased 
fruit, vegetables, and fish; less meat; 
reduced total fat and a greater ratio of 
polyunsaturated to saturated fat). There 
is no evidence for oily fish or omega-3 
fatty acid supplements as a preventative 
measure; and3
• GP review to optimise control of 
comorbidities that contribute to 
cardiovascular disease: patients with 
diabetes require good glycaemic control 
(HbA1C), and patients with hypertension 
should have a target clinic systolic blood 
pressure <140 mmHg.8
GETTING BACK TO NORMAL LIFE
Sexual intercourse
Sexual intercourse following MI bears no 
greater risk of a further MI than it did before, 
and can be resumed when patients feel 
comfortable to do so (usually 1 month). 
For erectile dysfunction, sildenafil and 
other phosphodiesterase-5 inhibitors 
are considered safe after 6 months in 
uncomplicated MIs, but are contraindicated 
in patients taking nitrates.3
Driving
Drivers do not need to notify the DVLA 
(unless they possess a specific bus, coach, 
or lorry licence), but must not drive for 
either 1 week (successful PCI and preserved 
LV systolic function, and no significant 
bystander coronary artery stenoses) or 
4 weeks (impaired LV systolic function, or 
remaining significant bystander coronary 
artery stenoses).
Flying
The UK Civil Aviation Authority recommends 
that low-risk patients (complication-free with 
no further treatment planned) can fly after 
10 days post-MI. If features of heart failure 
are present, or if there are plans for further 
treatment, patients should be considered 
high risk and should not fly without advice 
from a cardiologist. All patients should 
liaise with their travel operator, airline, and 
insurers before flying.3
CONCLUSION
GPs have an important role in overseeing 
effective secondary prevention following MI. 
This includes antiplatelet management, risk 
factor modification, lifestyle counselling, and 
management of comorbidities.
REFERENCES
1. Dondo TB, Hall M, Timmis AD, et al. Excess 
mortality and guideline-indicated care following 
non-ST-elevation myocardial infarction. Eur 
Heart J Acute Cardiovasc Care 2016; DOI: 
10.1177/2048872616647705.
2. Chung SC, Sundström J, Gale CP, et al. 
Comparison of hospital variation in acute 
myocardial infarction care and outcome 
between Sweden and United Kingdom: 
population based cohort study using nationwide 
clinical registries. BMJ 2015; 351: h3913; DOI: 
10.1136/bmj.h3913.
3. National Institute for Health and Care 
Excellence. Myocardial infarction: cardiac 
rehabilitation and prevention of further 
cardiovascular disease. CG172. 2013. https://
www.nice.org.uk/guidance/cg172 (accessed 23 
Jan 2018).
4. Ibanez B, James S, Agewall S, et al. 2017 
ESC Guidelines for the management of acute 
myocardial infarction in patients presenting 
with ST-segment elevation: the Task Force for 
the management of acute myocardial infarction 
in patients presenting with ST-segment 
elevation of the European Society of Cardiology 
(ESC). Eur Heart J 2017; DOI: 10.1093/
eurheartj/ehx393.
5. National Institute for Health and Care 
Excellence. Myocardial infarction with 
ST-segment elevation: acute management. 
CG167. 2013. https://www.nice.org.uk/
guidance/cg167/chapter/1-recommendations 
(accessed 23 Jan 2018).
6. National Institute for Health and Care 
Excellence. Unstable angina and NSTEMI: early 
management. CG94. 2010. https://www.nice.
org.uk/guidance/cg94 (accessed 23 Jan 2018).
7. Wilson K, Gibson N, Willan A, Cook D. Effect 
of smoking cessation on mortality after 
myocardial infarction: meta-analysis of cohort 
studies. Arch Intern Med 2000; 160(7): 939–944.
8. Task Force on the management of ST-segment 
elevation acute myocardial infarction of the 
European Society of Cardiology (ESC), Steg 
PG, James SK, et al. ESC Guidelines for the 
management of acute myocardial infarction in 
patients presenting with ST-segment elevation. 
Eur Heart J 2012; DOI: 10.1093/eurheartj/
ehs215.
Provenance
Freely submitted; externally peer reviewed. 
Competing interests
The authors have declared no competing 
interests.
Discuss this article
Contribute and read comments about this 
article: bjgp.org/letters
152  British Journal of General Practice, March 2018
